Updates, Insights & Perspectives

Summary Onconox Inc. has appointed Professor Justin Stebbing, a leading global oncologist, as Scientific and Medical Advisor to help shape the company’s scientific and clinical strategy for OCN001. His expertise strengthens Onconox’s preparations for IND-enabling activities and future clinical development. Both CEO Dr Sitaram Velaga and Professor Stebbing commented on the importance of this appointment. Onconox Inc., a biotechnology company dedicated to developing a novel the

Summary Onconox Inc. has successfully closed its seed funding round, securing capital to advance OCN001 through the next phase of its IND-enabling program. The raise builds on substantial preclinical progress already achieved under Kenox Pharmaceuticals, including a successful pre-IND meeting in 2021, and positions Onconox to accelerate the asset toward clinical evaluation. Onconox Inc., a biotechnology company dedicated to the development of a novel therapeutic candidate for

Summary Kenox Pharmaceuticals has established Onconox Inc. as a wholly owned subsidiary to advance OCN001, its investigational lung cancer therapy, into clinical development. The decision follows significant preclinical progress achieved within Kenox, including a successful pre-IND meeting in 2021. Full IP and development rights for OCN001 have been transferred to Onconox, enabling dedicated focus and streamlined progression toward clinical evaluation. Kenox Pharmaceuticals,